Webdisclosure.com

Search

MEDIOS AG Medios AG: Jefferies initiates coverage on Medios share with 'Hold' and price target ?41.00

Directive transparence : information réglementée

20/05/2020 10:03

DGAP-News: Medios AG / Key word(s): Study/Research Update
Medios AG: Jefferies initiates coverage on Medios share with 'Hold' and price target €41.00

20.05.2020 / 10:03
The issuer is solely responsible for the content of this announcement.


Press Release

Medios AG: Jefferies initiates coverage on Medios share with 'Hold' and price target €41.00

Berlin, 20 May 2020 - Jefferies Group LLC, the largest independent, global, full-service investment banking firm headquartered in the U.S., has today initiated coverage on Medios AG and issued a 'Hold' recommendation for the shares of the Specialty Pharma company. Accordingly, the price target amounts to €41.00 per share. The Medios share price currently stands at €36.40 (Xetra closing on 19 May 2020). In addition to Jefferies, Medios continues to be covered by Warburg, Berenberg and Kepler Cheuvreux.

-------------------

About Medios AG
Medios AG is one of the leading Specialty Pharma companies in Germany. As a specialist for the provision of Specialty Pharma drugs to patients, GMP-certified provider of patient-specific therapies and innovative analytical methods, Medios covers substantial elements of the supply chain in this field and follows the highest international quality standards. Usually, Specialty Pharma drugs are high-priced medicines for rare and/or chronic diseases. Patient-specific therapies are, for example, infusions that are compiled and produced on the basis of individual diseases and parameters like body weight and surface. In the field of drug safety, NIR spectroscopic analysis methods (NIR: Near infrared) are used to distinguish marketable finished drugs from drug counterfeits. It is Medios' aim to provide integrated solutions along the value chain to partners and clients, thereby ensuring an optimal pharmaceutical care for patients.

Medios AG is Germany's first publicly listed Specialty Pharma company. The shares (ISIN: DE000A1MMCC8, DE000A288821) are listed in the Regulated Market of the Frankfurt Stock Exchange (General Standard).

Contact
Kirchhoff Consult AG
Nikolaus Hammerschmidt
Borselstraße 20
22765 Hamburg
Germany
Phone: +49 40 60918618
Fax: +49 40 60918660
E-mail: nikolaus.hammerschmidt@kirchhoff.de
www.kirchhoff.de

Disclaimer
This notification contains forward-looking statements that are subject to certain risks and uncertainties. Future results may significantly deviate from currently expected results, specifically due to various risk factors and uncertainties such as changes in business, economic, and competitive circumstances, exchange rate fluctuations, uncertainties about legal disputes or investigations, and the availability of financial resources. Medios AG assumes no responsibility whatsoever for updating the forward-looking statements contained in this notification.



20.05.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: Medios AG
Heidestraße 9
10557 Berlin
Germany
Phone: +49 30 232 566 - 800
Fax: +49 30 232 566 - 801
E-mail: ir@medios.ag
Internet: www.medios.ag
ISIN: DE000A1MMCC8
WKN: A1MMCC
Listed: Regulated Market in Frankfurt (General Standard); Regulated Unofficial Market in Dusseldorf
EQS News ID: 1051607

 
End of News DGAP News Service

1051607  20.05.2020 

fncls.ssp?fn=show_t_gif&application_id=1051607&application_name=news&site_id=symex